Ximena Parraga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ximena Parraga has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Alan Bonder
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Behnam Saberi
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
4 shared publications - Juan Pablo Arab
Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
3 shared publications - Leandro Sierra
Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3 shared publications - Luis Antonio Díaz
Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
3 shared publications - Marwan Alsaqa
Division of Gastroenterology and Hepatology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (11)
Global Prognostic Impact of Substance Use in Alcohol‐Associated Hepatitis
Background and Aims: Alcohol‐associated hepatitis (AH) carries high short‐term mortality. Although concomitant substance use is common in patients with AH, its impact on clinical outcomes remains unclear. We aimed to determine the prevalence of active substance use and evaluate its association with clinical outcomes in a large, multinational cohort of hospitalized patients with AH. Methods: We conducted a prospective, multicenter study across 38 centers in 13 countries (2015–2024). Adults meeting National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for AH were enrolled. The primary outcome was all‐cause mortality stratified by substance use. Fine–Gray subdistribution hazard models were used to identify mortality predictors, with liver transplantation (LT) treated as a competing event. Results: We included 814 patients, with a mean age of 49.5 ± 10.6 years, and 88.8% were male. Active cannabis and cocaine use were reported in 6.1% and 5.5%, respectively. Over follow‐up, 210 patients (25.8%) died, and 35 (4.3%) underwent LT. In multivariable analysis, active cannabis use independently predicted higher mortality (sHR 2.49, 95% CI 1.52–4.09; p < 0.001), along with higher MELD scores and ACLF grades 2–3. Corticosteroid therapy (sHR 0.57, 95% CI 0.38–0.85; p = 0.007) and higher educational levels (sHR 0.34 and 0.31 for intermediate and highest categories, respectively) were associated with improved survival. Conclusions: Active substance use—particularly cannabis use—was independently associated with increased mortality in patients hospitalized with AH, even after adjusting for liver disease severity and accounting for transplantation as a competing event. These findings identify a behavioral dimension of AH severity and highlight the need to integrate addiction medicine and psychiatric care into hepatology practice to improve outcomes.
- 9 November 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (11)
Open AccessGlobal Prognostic Impact of Substance Use in Alcohol‐Associated Hepatitis
Background and Aims: Alcohol‐associated hepatitis (AH) carries high short‐term mortality. Although concomitant substance use is common in patients with AH, its impact on clinical outcomes remains unclear. We aimed to determine the prevalence of active substance use and evaluate its association with clinical outcomes in a large, multinational cohort of hospitalized patients with AH. Methods: We conducted a prospective, multicenter study across 38 centers in 13 countries (2015–2024). Adults meeting National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for AH were enrolled. The primary outcome was all‐cause mortality stratified by substance use. Fine–Gray subdistribution hazard models were used to identify mortality predictors, with liver transplantation (LT) treated as a competing event. Results: We included 814 patients, with a mean age of 49.5 ± 10.6 years, and 88.8% were male. Active cannabis and cocaine use were reported in 6.1% and 5.5%, respectively. Over follow‐up, 210 patients (25.8%) died, and 35 (4.3%) underwent LT. In multivariable analysis, active cannabis use independently predicted higher mortality (sHR 2.49, 95% CI 1.52–4.09; p < 0.001), along with higher MELD scores and ACLF grades 2–3. Corticosteroid therapy (sHR 0.57, 95% CI 0.38–0.85; p = 0.007) and higher educational levels (sHR 0.34 and 0.31 for intermediate and highest categories, respectively) were associated with improved survival. Conclusions: Active substance use—particularly cannabis use—was independently associated with increased mortality in patients hospitalized with AH, even after adjusting for liver disease severity and accounting for transplantation as a competing event. These findings identify a behavioral dimension of AH severity and highlight the need to integrate addiction medicine and psychiatric care into hepatology practice to improve outcomes.
- 23 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5630-5642
Splanchnic Vein Thrombosis after Metabolic and Bariatric Surgery: Chilean Position Statement of Hepatology and Bariatric Surgery societies
Background & Aims Metabolic and bariatric surgery is one of the most effective interventions for long-term weight loss and metabolic improvement. Splanchnic Vein Thrombosis (SVT) is an uncommon but potentially severe complication with a complex and multidisciplinary management, yet no clinical practice guidelines currently exist in this setting. We aimed to provide practical recommendations to guide healthcare teams in the prevention, diagnosis, and management of SVT after metabolic and bariatric surgery. Methods A modified Delphi process was conducted in two rounds among 17 experts (seven hepatologists, seven bariatric surgeons, and three interventional radiologists). Statements were generated based on a structured literature review. After the Delphi rounds, statements were refined considering rate and comments. Consensus was predefined as ≥ 80% agreement. Results Consensus was reached on seven dimensions of 20 statements (response rate R1 100% and R2 100%): (1) Risk factors related to surgical technique predisposing to SVT; (2) Assessment of candidates for metabolic and bariatric surgery; (3) Diagnosis of SVT; (4) Initial management of acute SVT; (5) Follow-up strategy for patients with SVT; (6) Late complications of SVT; (7) Prophylactic measures to prevent SVT. Recommendations emphasize the need for individualized surgical planning, comprehensive preoperative assessment for thrombotic risk factors, and multidisciplinary management. Additional statements addressed optimal diagnostic imaging, anticoagulation duration, and interventional radiology approaches for refractory or complicated cases. Conclusions This consensus provides structured, evidence-informed recommendations for the clinical assessment and management of SVT after metabolic and bariatric surgery. These statements are intended to standardize practice, support multidisciplinary decision-making, and improve patient outcomes in this rare but serious complication.
- 23 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5630-5642
Splanchnic Vein Thrombosis after Metabolic and Bariatric Surgery: Chilean Position Statement of Hepatology and Bariatric Surgery societies
Background & Aims Metabolic and bariatric surgery is one of the most effective interventions for long-term weight loss and metabolic improvement. Splanchnic Vein Thrombosis (SVT) is an uncommon but potentially severe complication with a complex and multidisciplinary management, yet no clinical practice guidelines currently exist in this setting. We aimed to provide practical recommendations to guide healthcare teams in the prevention, diagnosis, and management of SVT after metabolic and bariatric surgery. Methods A modified Delphi process was conducted in two rounds among 17 experts (seven hepatologists, seven bariatric surgeons, and three interventional radiologists). Statements were generated based on a structured literature review. After the Delphi rounds, statements were refined considering rate and comments. Consensus was predefined as ≥ 80% agreement. Results Consensus was reached on seven dimensions of 20 statements (response rate R1 100% and R2 100%): (1) Risk factors related to surgical technique predisposing to SVT; (2) Assessment of candidates for metabolic and bariatric surgery; (3) Diagnosis of SVT; (4) Initial management of acute SVT; (5) Follow-up strategy for patients with SVT; (6) Late complications of SVT; (7) Prophylactic measures to prevent SVT. Recommendations emphasize the need for individualized surgical planning, comprehensive preoperative assessment for thrombotic risk factors, and multidisciplinary management. Additional statements addressed optimal diagnostic imaging, anticoagulation duration, and interventional radiology approaches for refractory or complicated cases. Conclusions This consensus provides structured, evidence-informed recommendations for the clinical assessment and management of SVT after metabolic and bariatric surgery. These statements are intended to standardize practice, support multidisciplinary decision-making, and improve patient outcomes in this rare but serious complication.
- Open Access
- 4 August 2026
- Published by OAE Publishing Inc. in Metabolism and Target Organ Damage
- Vol. 6 (3)
Liver transplantation in patients with metabolic dysfunction and alcohol-related liver disease (MetALD)
Metabolic dysfunction and alcohol-related liver disease (MetALD) represents an increasingly recognized and clinically relevant phenotype within the steatotic liver disease (SLD) spectrum, although underreporting of alcohol intake leads to misclassification and underestimation of its true prevalence. In the liver transplantation (LT) setting, MetALD has become the third leading etiology among individuals waitlisted and undergoing transplant in the United States. This review examines the clinical implications of MetALD from candidate evaluation through post-liver transplantation (post-LT) follow-up. In the pre-liver transplantation (pre-LT), candidates with MetALD exhibit a narrower window for clinical recovery after decompensation. This translates into a higher adjusted risk of delisting due to death or clinical deterioration compared with other etiologies of SLD. After transplantation, MetALD is associated with worse outcomes than ALD alone, including higher all-cause mortality and graft failure, reflecting the synergistic hepatic injury driven by combined metabolic and alcohol-related mechanisms. Beyond liver-related events, the metabolic substrate of MetALD poses a high cardiovascular risk, highlighting the importance of integrated pre-LT and post-LT management that combines rigorous cardiometabolic assessment, objective alcohol-use monitoring, and targeted surveillance strategies specific to this population.
- 4 August 2026
- Published by OAE Publishing Inc. in Metabolism and Target Organ Damage
- Vol. 6 (3)
Open AccessLiver transplantation in patients with metabolic dysfunction and alcohol-related liver disease (MetALD)
Metabolic dysfunction and alcohol-related liver disease (MetALD) represents an increasingly recognized and clinically relevant phenotype within the steatotic liver disease (SLD) spectrum, although underreporting of alcohol intake leads to misclassification and underestimation of its true prevalence. In the liver transplantation (LT) setting, MetALD has become the third leading etiology among individuals waitlisted and undergoing transplant in the United States. This review examines the clinical implications of MetALD from candidate evaluation through post-liver transplantation (post-LT) follow-up. In the pre-liver transplantation (pre-LT), candidates with MetALD exhibit a narrower window for clinical recovery after decompensation. This translates into a higher adjusted risk of delisting due to death or clinical deterioration compared with other etiologies of SLD. After transplantation, MetALD is associated with worse outcomes than ALD alone, including higher all-cause mortality and graft failure, reflecting the synergistic hepatic injury driven by combined metabolic and alcohol-related mechanisms. Beyond liver-related events, the metabolic substrate of MetALD poses a high cardiovascular risk, highlighting the importance of integrated pre-LT and post-LT management that combines rigorous cardiometabolic assessment, objective alcohol-use monitoring, and targeted surveillance strategies specific to this population.
- 19 May 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (6) , 1343-1344
Rethinking endpoints in alcohol-associated hepatitis: A composite approach for real-world care
- 19 May 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (6) , 1343-1344
Rethinking endpoints in alcohol-associated hepatitis: A composite approach for real-world care
- Open Access
- 14 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8083
Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the United States and frequently coexists with other liver diseases. Despite growing interest, the presence of MASLD in patients with primary sclerosing cholangitis (PSC) remains underexplored. This study aimed to assess the prevalence and characteristics of the MASLD-PSC overlap syndrome, with a specific focus on patient-reported outcomes such as pruritus and fatigue. Methods: A cross-sectional analysis was performed within a prospective cohort of patients with PSC enrolled in the Autoimmune Liver Diseases Registry at a United States tertiary medical center (2018–2024). MASLD overlap was established based on evidence of hepatic steatosis on liver imaging or biopsy, combined with at least one cardiometabolic risk factor. Fatigue and pruritus were assessed using the Chronic Liver Disease Questionnaire (CLDQ) and the 5D Itch Scale. Ordinal logistic regression models were used to explore the potential impact of MASLD overlap on fatigue and pruritus severity. Results: Among 103 PSC patients, 33% had MASLD overlap. These patients were older (55 vs. 46 years, p = 0.006), had a higher BMI (30 vs. 25 kg/m2, p < 0.001), and were more likely to have small bile duct involvement (43% vs. 12%, p = 0.002). A history of liver transplantation (LT) was noted in 18% of PSC-only patients, compared to 3% of those with PSC/MASLD (p = 0.055). MASLD overlap was significantly associated with higher pruritus intensity (OR 3.09, 95% CI 1.02–9.28, p = 0.044), but was paradoxically linked to lower fatigue levels (OR 0.37, 95% CI 0.16–0.85, p = 0.020). Conclusions: Patients with PSC/MASLD exhibit distinct clinical features. MASLD overlap was found to significantly impact patient-reported outcomes, with lower fatigue intensity but increased pruritus severity, suggesting a role for metabolic or inflammatory pathways, warranting further investigation.
- 14 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8083
Open AccessImpact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the United States and frequently coexists with other liver diseases. Despite growing interest, the presence of MASLD in patients with primary sclerosing cholangitis (PSC) remains underexplored. This study aimed to assess the prevalence and characteristics of the MASLD-PSC overlap syndrome, with a specific focus on patient-reported outcomes such as pruritus and fatigue. Methods: A cross-sectional analysis was performed within a prospective cohort of patients with PSC enrolled in the Autoimmune Liver Diseases Registry at a United States tertiary medical center (2018–2024). MASLD overlap was established based on evidence of hepatic steatosis on liver imaging or biopsy, combined with at least one cardiometabolic risk factor. Fatigue and pruritus were assessed using the Chronic Liver Disease Questionnaire (CLDQ) and the 5D Itch Scale. Ordinal logistic regression models were used to explore the potential impact of MASLD overlap on fatigue and pruritus severity. Results: Among 103 PSC patients, 33% had MASLD overlap. These patients were older (55 vs. 46 years, p = 0.006), had a higher BMI (30 vs. 25 kg/m2, p < 0.001), and were more likely to have small bile duct involvement (43% vs. 12%, p = 0.002). A history of liver transplantation (LT) was noted in 18% of PSC-only patients, compared to 3% of those with PSC/MASLD (p = 0.055). MASLD overlap was significantly associated with higher pruritus intensity (OR 3.09, 95% CI 1.02–9.28, p = 0.044), but was paradoxically linked to lower fatigue levels (OR 0.37, 95% CI 0.16–0.85, p = 0.020). Conclusions: Patients with PSC/MASLD exhibit distinct clinical features. MASLD overlap was found to significantly impact patient-reported outcomes, with lower fatigue intensity but increased pruritus severity, suggesting a role for metabolic or inflammatory pathways, warranting further investigation.
- Open Access
- 16 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7306
Outcomes of Living-Donor Liver Transplantation for Cholangiocarcinoma Versus Hepatocellular Carcinoma in the United States
Objectives: Cholangiocarcinoma (CCA) is a malignancy of the biliary epithelium associated with high mortality. Hepatocellular carcinoma (HCC) is the most common primary liver tumor and has an established indication for liver transplant (LT). Living-donor LT (LDLT) may offer a curative and timely option for selected CCA patients. Methods: The United Network of Organ Sharing/Organ Procurement and Transplantation Network (UNOS/OPTN) data was reviewed from January 2010 to December 2022 for patients who underwent LDLT with HCC or CCA diagnostic codes. Post-LDLT survival for CCA was compared to HCC and non-HCC/CCA patients using Kaplan–Meier analysis. Stepwise multivariate analysis adjusted for recipient age, gender, race, and underlying etiology. Results: LDLT for CCA was most commonly performed in UNOS region 7 (54.9%) and region 2 (12.7%). Among 3993 LDLT recipients, 102 (2.6%) had CCA, 774 (19.4%) had HCC, and 3117 (78%) had neither HCC nor CCA. The 1-, 3- and 5-year post-LDLT survival of patients with CCA were 84.6%, 70.4%, and 62.2% versus 93.1%, 85.2%, and 78.2% for HCC, respectively. Conclusions: CCA accounts for 2.6% of LDLTs compared to 19.4% for HCC in the United States. At 5 years post-LDLT, patients with CCA have significantly lower survival compared to HCC.
- 16 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7306
Open AccessOutcomes of Living-Donor Liver Transplantation for Cholangiocarcinoma Versus Hepatocellular Carcinoma in the United States
Objectives: Cholangiocarcinoma (CCA) is a malignancy of the biliary epithelium associated with high mortality. Hepatocellular carcinoma (HCC) is the most common primary liver tumor and has an established indication for liver transplant (LT). Living-donor LT (LDLT) may offer a curative and timely option for selected CCA patients. Methods: The United Network of Organ Sharing/Organ Procurement and Transplantation Network (UNOS/OPTN) data was reviewed from January 2010 to December 2022 for patients who underwent LDLT with HCC or CCA diagnostic codes. Post-LDLT survival for CCA was compared to HCC and non-HCC/CCA patients using Kaplan–Meier analysis. Stepwise multivariate analysis adjusted for recipient age, gender, race, and underlying etiology. Results: LDLT for CCA was most commonly performed in UNOS region 7 (54.9%) and region 2 (12.7%). Among 3993 LDLT recipients, 102 (2.6%) had CCA, 774 (19.4%) had HCC, and 3117 (78%) had neither HCC nor CCA. The 1-, 3- and 5-year post-LDLT survival of patients with CCA were 84.6%, 70.4%, and 62.2% versus 93.1%, 85.2%, and 78.2% for HCC, respectively. Conclusions: CCA accounts for 2.6% of LDLTs compared to 19.4% for HCC in the United States. At 5 years post-LDLT, patients with CCA have significantly lower survival compared to HCC.
- 7 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 799-811
Evolving trends and comparative outcomes of bridging transarterial locoregional therapy in liver transplant candidates with hepatocellular carcinoma
Bridging locoregional therapy (LRT) is widely used in liver transplant (LT) candidates with hepatocellular carcinoma (HCC) to minimize waitlist dropout and evaluate tumor biology. While transarterial chemoembolization (TACE) has historically been the predominant approach, the role of transarterial radioembolization (TARE) is expanding. Comparative effectiveness data for these 2 modalities as bridging strategies remain limited. This study assessed the trends, factors influencing therapy selection, and outcomes of transarterial bridging LRT. We conducted a retrospective cohort study of adult LT candidates with HCC listed in the Organ Procurement and Transplantation Network (OPTN) between 2016 and 2024 who received TACE or TARE as their sole bridging LRT. Inverse probability weighting (IPW) was applied to balance baseline covariates. Multivariable Fine–Gray competing risk regression and stratified Cox proportional hazards and logistic regression models were used to assess waitlist dropout, complete pathological necrosis (CPN), recurrence, and overall survival. Among 8367 patients, 5472 (65%) received TACE, and 2895 (35%) received TARE. TARE use increased significantly from 22.5% to 51.7% over the study period. TARE was more likely to be used among patients with MASLD, older age, and high tumor burden, and less likely in those with lower socioeconomic status. TARE recipients had a significantly lower risk of waitlist dropout (sHR 0.83, p p p =0.19). The use of TARE as bridging therapy in HCC LT candidates has surged and is influenced by socioeconomic factors, comorbidities, and tumor burden. TARE effectiveness has been demonstrated by its advantages in waitlist retention and tumor necrosis. Further studies are warranted to evaluate its impact on post-LT recurrence and to validate the cost-effectiveness among transarterial therapies.
- 7 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 799-811
Evolving trends and comparative outcomes of bridging transarterial locoregional therapy in liver transplant candidates with hepatocellular carcinoma
Bridging locoregional therapy (LRT) is widely used in liver transplant (LT) candidates with hepatocellular carcinoma (HCC) to minimize waitlist dropout and evaluate tumor biology. While transarterial chemoembolization (TACE) has historically been the predominant approach, the role of transarterial radioembolization (TARE) is expanding. Comparative effectiveness data for these 2 modalities as bridging strategies remain limited. This study assessed the trends, factors influencing therapy selection, and outcomes of transarterial bridging LRT. We conducted a retrospective cohort study of adult LT candidates with HCC listed in the Organ Procurement and Transplantation Network (OPTN) between 2016 and 2024 who received TACE or TARE as their sole bridging LRT. Inverse probability weighting (IPW) was applied to balance baseline covariates. Multivariable Fine–Gray competing risk regression and stratified Cox proportional hazards and logistic regression models were used to assess waitlist dropout, complete pathological necrosis (CPN), recurrence, and overall survival. Among 8367 patients, 5472 (65%) received TACE, and 2895 (35%) received TARE. TARE use increased significantly from 22.5% to 51.7% over the study period. TARE was more likely to be used among patients with MASLD, older age, and high tumor burden, and less likely in those with lower socioeconomic status. TARE recipients had a significantly lower risk of waitlist dropout (sHR 0.83, p p p =0.19). The use of TARE as bridging therapy in HCC LT candidates has surged and is influenced by socioeconomic factors, comorbidities, and tumor burden. TARE effectiveness has been demonstrated by its advantages in waitlist retention and tumor necrosis. Further studies are warranted to evaluate its impact on post-LT recurrence and to validate the cost-effectiveness among transarterial therapies.
- Open Access
- 3 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7009
Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with liver transplantation (LT) offering a curative option for early-stage patients who cannot undergo resection. Although LT provides good long-term outcomes within standard criteria, recurrence occurs in approximately 8–20% of recipients and often leads to poor survival. Traditionally, LT eligibility relied on strict criteria like the Milan criteria, which are effective in selecting patients with low recurrence but may exclude patients who could benefit from transplantation. In response, new expanded criteria and models using tumor biology have been developed for better risk stratification, allowing more personalized selection and management. Despite these advances, recurrence remains a major clinical challenge, with no consensus on optimal imaging timing or frequency post-LT. Treatment depends on the recurrence’s extent and location, including surgical resection and locoregional therapies. Systemic treatments are promising, especially for unresectable or extrahepatic recurrence, though most evidence comes from small retrospective studies, limiting the development of standardized protocols. Future research should focus on addressing these gaps and guiding evidence-based post-transplant care. This is a narrative review summarizing recent advances in HCC recurrence.
- 3 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7009
Open AccessHepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with liver transplantation (LT) offering a curative option for early-stage patients who cannot undergo resection. Although LT provides good long-term outcomes within standard criteria, recurrence occurs in approximately 8–20% of recipients and often leads to poor survival. Traditionally, LT eligibility relied on strict criteria like the Milan criteria, which are effective in selecting patients with low recurrence but may exclude patients who could benefit from transplantation. In response, new expanded criteria and models using tumor biology have been developed for better risk stratification, allowing more personalized selection and management. Despite these advances, recurrence remains a major clinical challenge, with no consensus on optimal imaging timing or frequency post-LT. Treatment depends on the recurrence’s extent and location, including surgical resection and locoregional therapies. Systemic treatments are promising, especially for unresectable or extrahepatic recurrence, though most evidence comes from small retrospective studies, limiting the development of standardized protocols. Future research should focus on addressing these gaps and guiding evidence-based post-transplant care. This is a narrative review summarizing recent advances in HCC recurrence.